PATIENT SOLUTIONS

Lonnie, a patient on ENJAYMO

Support in your corner with Recordati Rare Diseases Patient Solutions (RRD PS)

RRD PS is here to help support you through your treatment journey.

If you have any questions about getting started with ENJAYMO, how it works, financial assistance, home infusions, or anything else related to treatment with ENJAYMO, call us at 1-833-223-2428 Monday through Friday, 8 AM to 8 PM ET.

Start today with the ENJAYMO No Cost Trial Program

Eligible patients* can experience 30 days of ENJAYMO (sutimlimab-jome) treatment at no cost
The ENJAYMO No Cost Trial Program is available to eligible patients regardless of insurance coverage or current treatment.

*PROGRAM OVERVIEW

The No Cost Trial Program can provide a 30-day supply of ENJAYMO at no cost to eligible patients.
Eligibility for the No Cost Trial Program is contingent on patient enrollment in RRD Patient Solutions.
There is no obligation for patients to continue to use ENJAYMO after the No Cost Trial Program has been completed.
Patients are eligible for the No Cost Trial Program only once per lifetime.
Shipment of the No Cost Trial Program product is contingent on the patients receiving recommended vaccinations and scheduling the first infusion.
After the No Cost Trial Program ends, you may be responsible for out-of-pocket costs from your health insurance.
The provision of the No Cost Trial Program product may be disclosed in accordance with transparency reporting requirements in certain states (e.g. VT).
Recordati Rare Diseases reserves the right to change, modify, or discontinue this program at any time without notice.

*ELIGIBILITY

You are using ENJAYMO for the first time.
You are being treated for an on-label indication.
You are 18 years of age or older.
You are a resident of the United States, Puerto Rico, or other U.S. territories.
You are being treated by a healthcare provider of the U.S. or its territories.

DOWNLOAD START FORM

Meet the team that is ready to support you throughout your treatment journey

When you enroll in RRD PS, you gain access to a dedicated team that can connect you with a wide range of resources. This team includes:

Case Managers (CMs)

Case Managers (CMs) can help you get started on treatment and assist with insurance–related needs
They’re available throughout your treatment journey to provide additional support

Therapeutic Education Managers (TEMs)

Therapeutic Education Managers, or TEMs, are available to provide education about ENJAYMO and Cold Agglutinin Disease
TEMs help raise awareness about Cold Agglutinin Disease in the community and educate patients and caregivers
They provide information and facilitate educational events about ENJAYMO and Cold Agglutinin Disease
Talk to your Case Manager to learn more about how to contact a TEM

TEMs are paid to provide educational services on behalf of Recordati Rare Diseases. They do not provide medical advice. You should always talk to your doctor about personal medical questions.

Nancy, a patient on ENJAYMO

Recordati Rare Diseases Patient Solutions Sign-up:

SIGN E-CONSENT FORM HERE

Financial assistance

The RRD Financial Assistance Programs are designed to provide support for eligible patients who wouldn't otherwise be able to access ENJAYMO. There are 2 options available:

The RRD ENJAYMO Patient Assistance Program

The ENJAYMO Patient Assistance Program provides support for eligible patients who have limited access to treatment due to insurance issues and other ﬁnancial challenges.

The RRD ENJAYMO Copay Assistance Program

The ENJAYMO Copay Assistance Program may be able to help eligible patients with treatment costs, such as out-of-pocket expenses, copayments, or coinsurance, for patients with commercial health insurance plans.*

*The RRD ENJAYMO Copay Assistance Program (the “Program”) is not valid for prescriptions covered by or submitted for reimbursement under Medicare, Medicaid, VA, DoD, TRICARE®, or similar federal or state programs, including any state pharmaceutical assistance programs. The Program is not valid where prohibited by law, and savings may vary depending on patients’ out-of-pocket costs and infusion costs. Recordati Rare Diseases reserves the right to modify or terminate the Program at any time without notice. Patients will receive all Program details upon registration.

ENJAYMO enrollment form

If you've been prescribed ENJAYMO, work with your doctor to complete the Recordati Rare Diseases enrollment form to get started with support services that are available to you.

DOWNLOAD ENROLLMENT FORM

Find the answers to your most frequently asked questions about Cold Agglutinin Disease

FAQS

Find educational materials you can take with you

RESOURCES

What is ENJAYMO?

ENJAYMO® is a prescription medicine used to treat the breakdown of red blood cells (hemolysis) in adults with cold agglutinin disease (CAD).

It is not known if ENJAYMO is safe and effective in children.

IMPORTANT SAFETY INFORMATION

Do not receive ENJAYMO if you are allergic to sutimlimab-jome or any of the ingredients in ENJAYMO.

ENJAYMO can cause serious side effects, including:

Serious Infections: ENJAYMO is a prescription medicine that affects your immune system. ENJAYMO may lower the ability of your immune system to fight infections. ENJAYMO increases your chance of getting serious infections including those caused by encapsulated bacteria, including Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae type B. These serious infections may quickly become life-threatening or cause death if not recognized and treated early.
- You must complete or be up to date with the vaccines against Streptococcus pneumoniae and Neisseria meningitidis at least 2 weeks before your first dose of ENJAYMO.
- If your healthcare provider decides that urgent treatment with ENJAYMO is needed, you should receive vaccinations as soon as possible.
- If you have been vaccinated against these bacteria in the past, you might need additional vaccines before starting ENJAYMO. Your healthcare provider will decide if you need additional vaccines.
- Vaccines do not prevent all infections caused by encapsulated bacteria. Call your healthcare provider or get emergency medical care right away if you get any of these signs and symptoms of a serious infection: fever with or without shivers or chills, fever with chest pain and cough, fever with high heart rate, headache and fever, confusion, clammy skin, fever and a rash, fever with breathlessness or fast breathing, headache with nausea or vomiting, headache with stiff neck or stiff back, body aches with flu-like symptoms, and/or eyes sensitive to light.
Infusion-related reactions: Treatment with ENJAYMO may cause infusion-related reactions, including allergic reactions that may be serious or life-threatening. Your healthcare provider may slow down or stop your ENJAYMO infusion if you have an infusion-related reaction and will treat your symptoms if needed. Tell your healthcare provider right away if you develop symptoms during your ENJAYMO infusion that may mean you are having an infusion-related reaction, including: shortness of breath, decrease in blood pressure, chest discomfort, rapid heartbeat, nausea, injection site reaction, flushing, headache, dizziness, rash, and itchy skin.
Risk of autoimmune disease: ENJAYMO may increase your risk for developing an autoimmune disease such as systemic lupus erythematosus (SLE). Tell your healthcare provider and get medical help if you develop any symptoms of SLE, including: joint pain or swelling, rash on the cheeks and nose, and unexplained fever.
If you have CAD and you stop receiving ENJAYMO, your healthcare provider should monitor you closely for return of your symptoms after you stop ENJAYMO. Stopping ENJAYMO may cause the breakdown of your red blood cells due to CAD to return. Symptoms or problems that can happen due to red blood cell breakdown include: tiredness, shortness of breath, rapid heart rate, and blood in your urine or dark urine.

The most common side effects of ENJAYMO include: increase in blood pressure, urinary tract infection, respiratory tract infection, bacterial infection, swelling in lower legs or hands, joint pain, headache, nausea, runny nose, bluish color to the lips and skin, dizziness, feeling tired or weak, cough, and changes in color or sensation in the fingers and toes (Raynaud’s phenomenon).

These are not all the possible side effects of ENJAYMO. Call your doctor for medical advice about side effects. You are encouraged to report side effects of prescription drugs to the FDA. Call 1-800-FDA-1088 or visit www.fda.gov/medwatch.

Before receiving ENJAYMO, tell your healthcare provider about all of your medical conditions, including if you: have a fever or infection, including a history of human immunodeficiency virus (HIV), hepatitis B, or hepatitis C; have an autoimmune disease such as systemic lupus erythematosus, also known as lupus; are pregnant or plan to become pregnant. It is not known if ENJAYMO will harm your unborn baby; are breastfeeding or plan to breastfeed. It is not known if ENJAYMO passes into your breast milk.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Please see Full Prescribing Information, including Medication Guide.